This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering

Novel Immuno-Oncology and Immunotherapeutic Approaches - WHITEPAPER


Download the exclusive whitepaper

The future is bright for antibody-based and cellular therapies for immuno-oncology, with the technologies of bispecifics and CAR-Ts converging. Bispecifics and CAR-Ts can be combined to create bispecific CAR-Ts. The technology is now not only limited to T-cells but is being applied to natural killer cells in the clinic. At the cutting-edge technologies such as TCR-T are targeting intracellular cancer epitopes. Antibodies alone can also be used to target intracellular proteins.

This whitepaper looks at the latest advances, technologies and challenges in immuno-oncology drug development, including:

  • CD3-Bispecifics vs CAR-T Cells

  • Bispecific or compound (cCAR-T) formats to overcome antigen escape

  • NanoCAR

  • CAR-NK and bispecific NK engagers, innately resistant to antigen escape

  • Autologous T-cells with enhanced TCR tumour antigen binding (SPEAR T-cells)

  • Targeting intracellular antigens such as RAS with antibodies

To download the exclusive whitepaper simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content.

ABOUT THE AUTHOR:  David Orchard-Webb, PhD, is a freelance consultant and medical/biotech writer.

This piece represents the views of the author and not necessarily the views of Informa Connect Life Sciences or the Antibody Therapeutics and Engineering conference series.

Have any questions about the whitepaper or interested in sponsoring a future whitepaper? Email

Log in or Create an Informa Connect Account to Access this content

Creating an account also means you'll get special access to article updates and exclusive industry content.